All In MedTech

FDA Clearance Tracker · P150035-S039

The AVEIR Leadless Pacemaker (LP)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 11, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 11, 2026

Approved

Time to decision

29 days

Received May 13, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P150035-S039
Device name
The AVEIR Leadless Pacemaker (LP)
Applicant location
Sylmar, CA
Received
May 13, 2026
Decided
Jun 11, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P150035

Device type

Device class
Class III
Regulation
21 CFR 870.3610

Every decision under product code PNJ

FDA's approval statement

As written in FDA's record.

approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P150035/S036

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.